NOS1AP protein levels are altered in BA46 and cerebellum of patients with schizophrenia

Schizophrenia Research

Volumn 124, Issue 1-3, 2010, Pages 248-250

  Hadzimichalis, Norell M ^a   Previtera, Michelle L ^a   Moreau, Michael P ^a   Li, Bo ^b,c   Lee, Gum Hwa ^a   Dulencin, Anna M ^a,c   Matteson, Paul G ^c   Buyske, Steven ^a   Millonig, James H ^a,c   Brzustowicz, Linda M ^a   Firestein, Bonnie L ^a  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEURONAL NITRIC OXIDE SYNTHASE; PROTEIN NOS1AP; UNCLASSIFIED DRUG;

BRAIN REGION; CEREBELLUM; HUMAN; HUMAN TISSUE; LETTER; NEUROTRANSMISSION; OCCIPITAL LOBE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SCHIZOPHRENIA; TEMPORAL LOBE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CEREBELLUM; FRONTAL LOBE; HUMANS; OCCIPITAL LOBE; POSTMORTEM CHANGES; PREFRONTAL CORTEX; PROTEIN ISOFORMS; SCHIZOPHRENIA; TEMPORAL LOBE;

EID: 78249244119     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2010.05.009     Document Type: Letter

References (11)

1. Avila M.T., Weiler M.A., Lahti A.C., Tamminga C.A., Thaker G.K. Effects of ketamine on leading saccades during smooth-pursuit eye movements may implicate cerebellar dysfunction in schizophrenia. Am. J. Psychiatry 2002, 159(9):1490-1496.
2. Barch D.M. The cognitive neuroscience of schizophrenia. Annu. Rev. Clin. Psychol. 2005, 1:321-353.
3. Brzustowicz L.M. NOS1AP in schizophrenia. Curr. Psychiatry Rep. 2008, 10(2):158-163.
4. Brzustowicz L.M., Simone J., Mohseni P., Hayter J.E., Hodgkinson K.A., Chow E.W., Bassett A.S. Linkage disequilibrium mapping of schizophrenia susceptibility to the CAPON region of chromosome 1q22. Am. J. Hum. Genet. 2004, 74(5):1057-1063.
5. Bunney W.E., Bunney B.G. Evidence for a compromised dorsolateral prefrontal cortical parallel circuit in schizophrenia. Brain Res. Brain Res. Rev. 2000, 31(2-3):138-146.
6. Jaffrey S.R., Snowman A.M., Eliasson M.J., Cohen N.A., Snyder S.H. CAPON: a protein associated with neuronal nitric oxide synthase that regulates its interactions with PSD95. Neuron 1998, 20(1):115-124.
7. Kapoor R., Lim K.S., Cheng A., Garrick T., Kapoor V. Preliminary evidence for a link between schizophrenia and NMDA-glycine site receptor ligand metabolic enzymes, d-amino acid oxidase (DAAO) and kynurenine aminotransferase-1 (KAT-1). Brain Res. 2006, 1106(1):205-210.
8. Burnham KPaA, David R. Model Selection and Multimodel Inference: a Practical Information-Theoretic Approach 2002, Springer-Verlag, New York, New York.
9. Toro C., Deakin J.F.W. NMDA receptor subunit NRI and postsynaptic protein PSD-95 in hippocampus and orbitofrontal cortex in schizophrenia and mood disorder. Schizophr. Res. 2005, 80(2-3):323-330.
10. Wratten NS Memoli H., Huang Y., Dulencin AM Matteson P.G., Cornacchia M.A., Azaro MA Messenger J., Hayter JE Bassett A.S., et al. Identification of a schizophrenia-associated functional noncoding variant in NOS1AP. Am. J. Psychiatry 2009, 166(4):434-441.
11. Xu B., Wratten N., Charych E.I., Buyske S., Firestein B.L., Brzustowicz L.M. Increased expression in dorsolateral prefrontal cortex of CAPON in schizophrenia and bipolar disorder. PLoS Med. 2005, 2(10):e263.